Search Tag: AstraZeneca
2024 21 May
Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios Investing in disruptive innovation that will shape the future of medicine and drive long-term growth Decoupling carbon emissions from revenue growth AstraZeneca revealed its bold ambition to deliver...Read more
2024 21 May
Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios Investing in disruptive innovation that will shape the future of medicine and drive long-term growth Decoupling carbon emissions from revenue growth AstraZeneca revealed its bold ambition to deliver...Read more
2024 08 May
AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic. The company also said it would proceed to withdraw the vaccine Vaxzevria's marketing authorizations within Europe. "As multiple, variant COVID-19 vaccines have since...Read more
2024 05 Feb
Noémie Paillon has assumed the role of Assistant Medical Oncology and Haematology Project Manager at AstraZeneca. With a robust background in immuno-oncology, she brings a wealth of experience and a unique set of skills to her new position. Noémie characterises herself as a doctor who possesses excellent communication skills, a natural...Read more
2022 23 Mar
Huma acquires AstraZeneca’s digital health platform AMAZE™ and AstraZeneca becomes a shareholder of Huma Huma announced a new partnership with AstraZeneca to scale innovation for digital health. This agreement follows prior use cases executed between Huma and AstraZeneca, reflecting a shared ambition to improve clinical outcomes through digital...Read more
2022 13 Jan
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha and Gamma variants following third dose booster with Vaxzevria Additional analysis showed increased antibody response to Omicron after a third dose Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial...Read more
2021 20 Apr
Over the last week the COVID-19 vaccine landscape has once again changed drastically, with the use of J&J’s Janssen suspended in many countries and new players attracting more attention. You might also like: Shortages of COVID-19 vaccine supplies are being felt globally, not excluding the EU and the UK. Do companies fulfil their obligations...Read more
2021 30 Mar
The Anglo-Swedish pharmaceutical company AstraZeneca has changed the name of its COVID-19 vaccine. You might also like: Shortages of COVID-19 vaccine supplies are being felt globally, not excluding the EU and the UK. Do companies fulfil their obligations and where will new manufacturing facilities be created? Learn more The vaccine...Read more
2021 29 Mar
Shortages of COVID-19 vaccine supplies are being felt globally, not excluding the EU and the UK. Do companies fulfil their obligations and where will new manufacturing facilities be created? You might also like: Why has AstraZeneca’s COVID-19 vaccine been the centre of attention in Europe over the past few days? Learn more...Read more
2021 14 Mar
AstraZeneca’s COVID-19 vaccine has been the centre of attention in Europe over the past few days. Several countries has suspended its administration after reports of a number of thromboembolic events and several deaths. This has been exacerbated by the company’s inability to meet its contractual obligations in the EU on the medicine delivery....Read more
2021 23 Jan
COVAX, the global initiative to ensure equitable access to COVID-19 vaccines across the world, has announced new agreements for Pfizer/BioNTech and AstraZeneca/Oxford vaccines delivery, about 200 million doses in total. You might also like: COVID-19 Vaccines: Tracking and Future Distribution Specifically,...Read more
2020 02 Dec
The UK, first in the world, authorises Pfizer COVID-19 vaccine and is looking into fast-tracking AstraZeneca’s. In the meantime, Pfizer and Moderna both file applications for their vaccines’ emergency use in the U.S. and Europe. You might also like: Coronavirus, Tensegrity and CSR: Year of Living Dangerously The...Read more
2020 18 Nov
Pfizer has completed the Phase 3 of its COVID-19 vaccine trial and is ready to seek authorisation for emergency use in the U.S. The vaccine is reported to be 95% effective. Two other vaccine candidates, those of Moderna and the Russian Gamaleya Research Institute, demonstrated 94.5% and 92% efficacy, respectively, but the trials are still...Read more
2020 23 Oct
This week has seen another COVID-19 vaccine-related incident: a volunteer in the AstraZeneca (AZ) vaccine trial in Brazil has died. Nevertheless, the trial continues as might the previously halted Johnson & Johnson’s (J&J) and the U.S. arm of AZ’s trial. You might also like: Rushing COVID-19 Vaccine Development: Is It Justified?...Read more
2020 08 Jun
UK-based drugmaker AstraZeneca expands its plans with regard to the COVID-19 vaccine, doubling its manufacturing capacity to 2 billion doses and securing deals with a number of partners. You might also like: EU Supports Clinical Trials During COVID-19 The vaccine, AZD1222 (previously known as ChAdOx1 nCoV-19), was developed...Read more
2019 16 Jul
Jonathan Symonds CBE, former CFO of AstraZeneca and Novartis has been appointed to chairman at GlaxoSmithKline in the wake of the pharmaceutical company’s break-up. Symonds is currently overseeing operations at HSBC, and will replace Sir Philip Hampton, non-executive chairman at GlaxoSmithKline for the past four years. Symonds has previously...Read more
2016 27 Feb
Stockholm is cranking up the volume when it comes to life science opportunities. For healthcare, for the life science industry and for researchers. But most importantly – for you and me as future or current care recipients. The city is currently in the process of transforming a former railway depot into a flourishing life science arena. The area...Read more